Marekani - Kiingereza - NLM (National Library of Medicine)

bliss gvs pharma limited - hard fat (unii: 8334lx7s21) (hard fat - unii:8334lx7s21), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - protectant vasoconstrictor - temporarily shrinks hemorrhoidal tissue - temporarily relieves the itching, burning and discomfort associated with hemorrhoids

Marekani - Kiingereza - NLM (National Library of Medicine)

major pharmaceuticals - hard fat (unii: 8334lx7s21) (hard fat - unii:8334lx7s21), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - protectant vasoconstrictor - temporarily shrinks hemorrhoidal tissue - gives temporary relief to the itching, burning and discomfort associated with hemorrhoids

Marekani - Kiingereza - NLM (National Library of Medicine)

cardinal health, inc. - phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv), fat, hard (unii: 8334lx7s21) (fat, hard - unii:8334lx7s21) - phenylephrine hydrochloride 5.77 mg - ● protectant ● vasoconstrictor • helps relieve the local itching and discomfort associated with hemorrhoids • temporarily relieves burning and shrinks hemorrhoidal tissue • temporarily provides a coating for relief of anorectal discomforts • temporarily protects the inflamed, irritated anorectal surface to help make bowel movements less painful

Marekani - Kiingereza - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv), fat, hard (unii: 8334lx7s21) (fat, hard - unii:8334lx7s21) -

Marekani - Kiingereza - NLM (National Library of Medicine)

major pharmaceuticals - phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv), fat, hard (unii: 8334lx7s21) (fat, hard - unii:8334lx7s21) - - temporarily shrinks hemorrhoidal tissue - temporarily relieves the itching, burning and discomfort associated with hemorrhoids

Marekani - Kiingereza - NLM (National Library of Medicine)

rugby laboratories - phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv), fat, hard (unii: 8334lx7s21) (fat, hard - unii:8334lx7s21) - - temporarily shrinks hemorrhoidal tissue - temporarily relieves the itching, burning and discomfort associated with hemorrhoids

Marekani - Kiingereza - NLM (National Library of Medicine)

wockhardt limited - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 100 mg - bupropion hydrochloride extended-release tablets (sr) are indicated for the treatment of major depressive disorder. the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of depressed inpatients and in one 6-week controlled trial of depressed outpatients whose diagnoses corresponded most closely to the major depression category of the apa diagnostic and statistical manual (dsm) (see clinical pharmacology). a major depressive episode (dsm-iv) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a

Marekani - Kiingereza - NLM (National Library of Medicine)

wockhardt limited - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder. the efficacy of venlafaxine hydrochloride extended-release capsules in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii-r or dsm-iv category of major depressive disorder (see clinical trials ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessn

Marekani - Kiingereza - NLM (National Library of Medicine)

wockhardt usa llc. - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone hydrochloride capsule is indicated for the treatment of schizophrenia. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.2) ]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.2)]   ziprasidone hydrochloride capsule is indicated for the treatment of schizophrenia. the efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatients

Marekani - Kiingereza - NLM (National Library of Medicine)

wockhardt limited - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone hydrochloride capsule is indicated for the treatment of schizophrenia. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.2)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.2)] ziprasidone hydrochloride capsule is indicated for the treatment of schizophrenia. the efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatients an